Exchange Bulletin
MedReleaf Corp. (LEAF) To Trade On Toronto Stock Exchange
June 5, 2017
| Issuer: | MedReleaf Corp. (the "Company") |
| Security: | Common shares (the "Shares") |
| Symbol(s): | LEAF |
| Issue price per security: | $9.50 |
| Number of securities issued and outstanding: | 90,374,948 |
| Number of securities reserved for issuance: | 10,144,178 |
| Listing category: | Industrial, Exempt |
| CUSIP: | 58506X 10 4 |
| Trading currency: | CDN$ |
| Transaction: | Initial public offering (the "Offering"). |
| Listing date: | June 6, 2017 (as at 5:01 pm) in anticipation of closing of the Offering. |
| Anticipated closing date: | June 7, 2017 (prior to the opening) |
| Posted for trading date: | June 7, 2017 (at the opening) subject to confirmation of closing of the Offering. |
| Other market(s): | None |
| Temporary market maker: | TD Securities Inc. |
| Security ownership registration: | Non-certificated inventory |
| Investor relations: | Dennis Fong 416-283-9930 Email: dennis.fong@loderockadvisors.com |
| Incorporation: | Business Corporations Act (Ontario) |
| Fiscal year end: | March 31 |
| Nature of business: | The Company is a licensed producer of cannabis-based pharmaceutical products. The Company cultivates and produces its cannabis-based pharmaceutical products including dried cannabis, cannabis oils, and cannabis oil capsules. |
| Transfer agent and registrar: | TSX Trust Company at its principal office in Toronto. |
| Dividends: | The Company has not paid dividends to its shareholders to date and does not anticipate paying cash dividends on the Shares in the foreseeable future. |
| Sponsorship: | Waived |
| Disclosure document: | Prospectus dated May 30, 2017 which is available at www.SEDAR.com. |
| Initial public offering: | 10,600,000 Shares are being offered to the public at a price of $9.50 per Share (the "Offering Price") consisting of: (i) 8,494,742 Shares from treasury; and (ii) 2,105,258 Shares from selling shareholders ("Selling Shareholders") of the Company. In addition, the underwriters have been granted an over-allotment option to purchase up to an additional 1,590,000 Shares from the Company and Selling Shareholders at the Offering Price on an approximate 40%/60% basis. |
| TSX contact: | Julie K. Shin, Director, Listed Issuer Services, Toronto Stock Exchange. |